Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer
about
Genetic variations in radiation and chemotherapy drug action pathways and survival in locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapyAssessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group StudyPre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group studyMMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies.Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy.ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapyPolymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patientsPolymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome.Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes.Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.Overexpression of S100A14 in human serous ovarian carcinomaImpact of molecular profiling on overall survival of patients with advanced ovarian cancer.Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance.Genetic markers for prediction of treatment outcomes in ovarian cancer.Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma.Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy.Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.
P2860
Q28536735-C4FA10A1-A8FB-482E-8C9E-1EE679F2313EQ30417640-61940474-614E-4627-BCC3-4D9FD4BF49CAQ30419554-28C00792-35CC-4F7A-8DF0-FD2FABD96968Q33570512-C34E03DA-F96F-4310-A76B-0615F42A7E8CQ33880468-0120515D-0DD8-412D-8DCF-C47FD6D56FCEQ33959550-4FBFDA52-B112-48E0-817F-40CEC482CF21Q33985880-06964F9C-7A75-484B-9EB8-ECB98A6EB45EQ34256001-8B183676-ADB4-4A0A-B85F-CDDF131479B7Q34742602-08217D6A-43F9-40ED-87E4-FEA631C3DB87Q34745772-A2194D8A-8B8B-46E7-BFAA-6976710373AAQ35031998-1311C9FD-3518-4EE5-B1E0-8FBF653982BCQ35584647-C25528B3-F623-44FB-B32A-9494A8F19CC8Q35815416-60A9C354-B704-4EBB-A050-BF47D13965DEQ36457582-D6DFFBF9-12AB-4138-B31D-C5D2E6C82E36Q36524069-27A29334-1010-4736-8AC0-E9DE37026DF6Q37190190-AB2277B7-C37C-4D56-BAFE-449A696FF34DQ37722147-9911CC0E-31CF-4A1E-BFCA-D8EE6731FD2FQ38227080-69D8CC90-D528-4D5B-AE58-212AB8C8E5E3Q38276429-1E5B0487-AEE5-4043-BCED-820A4A5D8A6DQ41758054-CF71F152-4A2A-4AA1-BC86-4B8BB0960FBFQ42755164-4575C6E9-28FC-46D5-9316-A893FF3E62C2Q43951894-81824F03-7005-40A3-83C3-2019C0D8B91DQ46063656-E7F573B1-13BB-4899-9394-869F7A066628Q47876292-41CABF6D-3C6D-4908-84D9-EE640E99C003
P2860
Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Relationship between ERCC1 pol ...... III epithelial ovarian cancer
@ast
Relationship between ERCC1 pol ...... III epithelial ovarian cancer
@en
type
label
Relationship between ERCC1 pol ...... III epithelial ovarian cancer
@ast
Relationship between ERCC1 pol ...... III epithelial ovarian cancer
@en
prefLabel
Relationship between ERCC1 pol ...... III epithelial ovarian cancer
@ast
Relationship between ERCC1 pol ...... III epithelial ovarian cancer
@en
P2093
P2860
P356
P1476
Relationship between ERCC1 pol ...... III epithelial ovarian cancer
@en
P2093
Bora E Baysal
Chunqiao Tian
Deborah Armstrong
Gynecologic Oncology Group Phase III Trial
Holly Gallion
Julie A DeLoia
Kathleen M Darcy
Thomas C Krivak
P2860
P304
P356
10.1200/JCO.2008.16.1323
P407
P577
2008-07-01T00:00:00Z